48
Views
9
CrossRef citations to date
0
Altmetric
Research Article

Long-term Effects of Losartan on Proteinuria and Renal Function in Patients with Renal Amyloidosis

, , , , , & show all
Pages 443-446 | Published online: 09 Jul 2009

REFERENCES

  • Ruggenenti P, Remuzzi G. Angiotensin-converting enzyme inhibitor therapy for non-diabetic progressive renal disease. Curr Opin Nephrol Hypertens 1997; 6: 489–95.
  • El Nahas AM. Renal scarring: the role of angiotensin II. Nephrol Dial Transplant 1995; 10 (Suppl 9): 28–32.
  • Perico N, Remuzzi G. Angiotensin II receptor antago-nists and treatment of hypertension and renal disease. Curr Opin Nephrol Hypertens 1998; 7: 571–8.
  • Schwartz MM. The dysproteinemias and amyloidosis. In: Jennette JC, Olson JL, Schwartz MIVI, Silva FG, eds. Heptinstall's pathology of the kidney. Philadelphia, PA: Lippincott-Raven, 1998: 1321–69.
  • Adler SG, Cohen AH, Glassock RJ. Secondary glom-erular diseases. In: Brenner BM, ed. The kidney. Philadelphia, PA: Saunders, 1996: 1498–596.
  • Wegelius D, Wafin F, Falck HM, Tornroth T. Follow-up study of amyloidosis secondary to rheumatic disease. In: Glenner GG, Costa PP, Tornroth T, Freitas AF, eds. Amyloid and amyloidosis. Amsterdam: Excerpta Medica, 1980: 183–90.
  • Schena FP, Pannarale G, Carbonara MC. Clinical and therapeutic aspects of renal amyloidosis. Nephrol Dial Transplant 1996; 11 (Suppl 9): 63–8.
  • Ruggenenti P, Perna A, Mosconi L, Matalone M, Garini G, Salvadori M, et al. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non diabetic nephropathy. Lancet 1997; 349: 1857–63.
  • Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet 1998; 352: 1252–6.
  • Gansevoort RT, De Zeeuw D, De Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994; 45: 861–7.
  • Usta M, Dilek K, Yavuz M, Ersoy A, GullUlu M, Yavuz M, et al. Anti-proteinuric effect of angiotensin receptor antagonist losartan in cases with glomerular lesions. Clin Nephrol 2001; 55: 260–2.
  • Bidani AK, Griffin KA, Bakris G, Picken MIVI. Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation. Kidney Int 2000; 57: 1651–61.
  • Morelli E, Loon N, Meyer T, Peters W, Myers BD. Effects of converting enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes 1990; 39: 76–82.
  • Remuzzi A, Perticucci E, Ruggenenti P, Mosconi L, Limonta M, Remuzzi G. Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. Kidney Int 1991; 39: 1267–73.
  • Wu LL, Cox A, Roe CJ, Dziadek M, Cooper ME, Gilbert RE. Transforming growth factor beta 1 and renal injury following subtotal nephrectomy in the rat: role of the renin-angiotensin system. Kidney Int 1997; 51: 1553–67.
  • Morrissey JJ, Klahr S. Differential effects of ACE and ATi receptor inhibition on chemoattractant and adhesion molecule synthesis. Am J Physiol 1998; 274: F580–6.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.